GEOVAX LABS INC

NASDAQ: GOVX (GeoVax Labs, Inc.)

Kemas kini terakhir: semalam, 9:50AM

1.68

-0.63 (-27.27%)

Penutupan Terdahulu 2.31
Buka 2.34
Jumlah Dagangan 617,713
Purata Dagangan (3B) 142,215
Modal Pasaran 2,910,008
Harga / Jualan (P/S) 0.580
Harga / Buku (P/B) 1.11
Julat 52 Minggu
1.63 (-3%) — 47.13 (2705%)
Tarikh Pendapatan 19 Mar 2026
Margin Operasi (TTM) -330.18%
EPS Cair (TTM) -2.80
Nisbah Semasa (MRQ) 2.55
Aliran Tunai Operasi (OCF TTM) -24.68 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -16.53 M
Pulangan Atas Aset (ROA TTM) -915.19%
Pulangan Atas Ekuiti (ROE TTM) -78,814.56%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok GeoVax Labs, Inc. Bercampur Menurun

AISkor Stockmoo

1.0
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal -0.5
Purata 1.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
GOVX 3 M - - 1.11
MRNA 17 B - - 1.68
JAZZ 10 B - - 2.55
COGT 6 B - - 29.26
CELC 5 B - - 41.32
SYRE 3 B - - 9.04

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 0.42%
% Dimiliki oleh Institusi 7.72%

Pemilikan

Nama Tarikh Syer Dipegang
Fiduciary Alliance Llc 31 Dec 2025 1,400
Moneta Group Investment Advisors Llc 31 Dec 2025 800
Julat 52 Minggu
1.63 (-3%) — 47.13 (2705%)
Median 6.00 (257.14%)
Jumlah 1 Beli
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
D. Boral Capital 21 Jan 2026 6.00 (257.14%) Beli 2.98
19 Nov 2025 6.00 (257.14%) Beli 10.38

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
20 Jan 2026 Pengumuman GeoVax Highlights 2026 as a Pivotal Year for Progress
08 Jan 2026 Pengumuman GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
06 Jan 2026 Pengumuman GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week
19 Dec 2025 Pengumuman GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
18 Dec 2025 Pengumuman GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine
18 Dec 2025 Pengumuman GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA
17 Dec 2025 Pengumuman GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026
16 Dec 2025 Pengumuman GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design
15 Dec 2025 Pengumuman GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
11 Dec 2025 Pengumuman GeoVax Addresses Identification of New Mpox Variant
10 Dec 2025 Pengumuman GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board
09 Dec 2025 Pengumuman GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy
08 Dec 2025 Pengumuman GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer
24 Nov 2025 Pengumuman GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda